← 產業報告目錄
Next Generation Drug Conjugates Market Size, Share & Trends Analysis Report, By Type (Peptide Receptor Radionuclide Therapy, Ligand mediated RNAi Conjugate, Ligand Conjugated Anti Sense Medicine and Peptide Drug Conjugate), By Type of Targeting Ligand (Amino Sugar, Peptide, Lipid, Small Molecule and Virus-like Particles), By Type of Payload (Peptide, Small Molecule, Oligonucleotide, Radionuclide), By Type of Therapy (Monotherapy, Combination Therapy), By Route of Administration, By Target Indications, By Region, Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-12頁數 180報告編號 INSIGHTACE-ccf94a039d
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
In 2024, the Next Generation Drug Conjugates Market worldwide was assessed at USD 2.9 Bn. Analysts project it will surge to USD 12.1 Bn by 2034, at a CAGR of 15.2% spanning 2025 to 2034.
Next Generation Drug Conjugates encompasses The next-generation drug conjugates (NGDCs) market represents a paradigm shift in cancer therapy, leveraging the synergistic potential of targeted drug delivery and enhanced therapeutic efficacy. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Market momentum is bolstered by growing interest in advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
From a regional perspective, mature markets in North America and Europe continue to hold meaningful shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and growing investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Next Generation Drug Conjugates Market Snapshot
Chapter 4. Global Next Generation Drug Conjugates Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type of Next Generation Drug Conjugates Estimates & Trend Analysis
5.1. by Type of Next Generation Drug Conjugates & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Next Generation Drug Conjugates :
5.2.1. Peptide Receptor Radionuclide Therapy (Peptide Radionuclide Conjugate)
5.2.2. Ligand mediated RNAi Conjugate
5.2.3. Ligand Conjugated Anti Sense Medicine
5.2.4. Peptide Drug Conjugate
Chapter 6. Market Segmentation 2: by Type of Targeting Ligand Estimates & Trend Analysis
6.1. by Type of Targeting Ligand & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Targeting Ligand:
6.2.1. Amino Sugar
6.2.2. Lipid
6.2.3. Peptide
6.2.4. Small Molecule
6.2.5. Virus-like Particles
Chapter 7. Market Segmentation 3: by Type of Payload Estimates & Trend Analysis
7.1. by Type of Payload & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Payload:
7.2.1. Peptide
7.2.2. Small Molecule
7.2.3. Oligonucleotide
7.2.4. Radionuclidea
Chapter 8. Market Segmentation 4: by Type of Therapy Estimates & Trend Analysis
8.1. by Type of Therapy & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Therapy:
8.2.1. Monotherapy
8.2.2. Combination Therapy
Chapter 9. Market Segmentation 5: by Route of Administration Estimates & Trend Analysis
9.1. by Route of Administration & Market Share, 2024 & 2034
9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Route of Administration:
9.2.1. Intravenous
9.2.2. Subcutaneous
9.2.3. Others
Chapter 10. Market Segmentation 6: by Target Indications Estimates & Trend Analysis
10.1. by Target Indications & Market Share, 2024 & 2034
10.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Target Indications:
10.2.1. Gastroenteropancreatic Neuroendocrine Tumors
10.2.2. Prostate Cancer
10.2.3. Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases
10.2.4. Hereditary Transthyretin Amyloidosis
10.2.5. Atherosclerotic Cardiovascular Diseases
10.2.6. Severe Hypertriglyceridemia
10.2.7. Hereditary Angioedema
10.2.8. Acute Hepatic Porphyria
10.2.9. Primary Hyperoxaluria
10.2.10. Heterozygous Familial Hypercholesterolemia
10.2.11. Hemophilia
10.2.12. Low-Risk Myelodysplastic Syndrome
10.2.13. Myelofibrosis
10.2.14. Familial Chylomicronemia Syndrome
10.2.15. Alpha-1 Antitrypsin Deficiency Liver Disease
Chapter 11. Next Generation Drug Conjugates Market Segmentation 7: Regional Estimates & Trend Analysis
11.1. North America
11.1.1. North America Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Next Generation Drug Conjugates, 2021-2034
11.1.2. North America Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Targeting Ligand, 2021-2034
11.1.3. North America Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Payload , 2021-2034
11.1.4. North America Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Therapy, 2021-2034
11.1.5. North America Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration,2021-2034
11.1.6. North America Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Target Indications, 2021-2034
11.1.7. North America Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
11.2. Europe
11.2.1. Europe Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Next Generation Drug Conjugates, 2021-2034
11.2.2. Europe Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Targeting Ligand, 2021-2034
11.2.3. Europe Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Payload, 2021-2034
11.2.4. Europe Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Therapy, 2021-2034
11.2.5. Europe Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration,2021-2034
11.2.6. Europe Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Target Indications,2021-2034
11.2.7. Europe Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
11.3. Asia Pacific
11.3.1. Asia Pacific Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Next Generation Drug Conjugates, 2021-2034
11.3.2. Asia Pacific Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Targeting Ligand, 2021-2034
11.3.3. Asia-Pacific Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Payload , 2021-2034
11.3.4. Asia Pacific Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Therapy, 2021-2034
11.3.5. Asia Pacific Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration,2021-2034
11.3.6. Asia Pacific Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Target Indications, 2021-2034
11.3.7. Asia Pacific Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
11.4. Latin America
11.4.1. Latin America Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Next Generation Drug Conjugates, 2021-2034
11.4.2. Latin America Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Targeting Ligand, 2021-2034
11.4.3. Latin America Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Payload , 2021-2034
11.4.4. Latin America Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Therapy ,2021-2034
11.4.5. Latin America Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
11.4.6. Latin America Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Target Indications, 2021-2034
11.4.7. Latin America Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
11.5. Middle East & Africa
11.5.1. Middle East & Africa Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Next Generation Drug Conjugates, 2021-2034
11.5.2. Middle East & Africa Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Targeting Ligand, 2021-2034
11.5.3. Middle East & Africa Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Payload , 2021-2034
11.5.4. Middle East & Africa Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Type of Therapy , 2021-2034
11.5.5. Middle East & Africa Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration,2021-2034
11.5.6. Middle East & Africa Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by Target Indications, 2021-2034
11.5.7. Middle East & Africa Next Generation Drug Conjugates Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. Advanced Accelerator Applications
12.2.2. Alnylam Pharmaceuticals
12.2.3. Arrowhead Pharmaceuticals
12.2.4. Dicerna Pharmaceuticals
12.2.5. Geron Corporation
12.2.6. Ionis Pharmaceuticals
12.2.7. Other Prominent Players
12.2.7. Dyne Therapeutics, Inc.
12.2.8. Ambrx Biopharma, Inc. (Johnson & Johnson Services, Inc.)
12.2.9. Vincerx Pharma
12.2.10. Tubulis Technologies
12.2.11. Nurix Therapeutics, Inc.
12.2.12. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們